Beginning in 1997, the Food and Drug Administration (FDA) allowed television advertisements to make major statements about a prescription drug, while referring to detailed information on the internet. The hope was that consumers would seek additional information online to understand the risks and benefits of taking the medication. This policy motivates us to analyze direct-to-consumer advertising (DTCA) and search engine click-through data on a set of drugs over the period from 2008 to 2011.
Introduction
Advertising regulations have extended from traditional medias to the internet. Take prescription drugs for example: in 1997, the Food and Drug Administration (FDA) allowed a television advertisement to focus on the essential efficacy and side effect information of a prescription drug as long as the manufacturer provided detailed drug information on the internet and in other publications (FDA 1997; . 1 The key assumptions are that (1) a television-watching consumer will seek more information on the internet, and (2) this process will result in a balanced understanding of the drug.
Our paper contributes to the recent literature assessing both assumptions. On the first, Kim (2015) analyzed warning letters issued to pharmaceutical companies regarding problems with their online search ads and found that most violations were for a lack of adequate risk information on branded drug websites and in online paid advertisements. After receiving these letters, many of the advertisements were removed. Choiu and Tucker (2016) looked at how search patterns changed as a result and found that consumers were more likely to click on websites that featured user-generated content and online pharmacies.
Beyond drug advertising, a number of papers have looked at the relationship between television advertising and online search. Joo et al. (2014) look at how television advertisements for financial services companies affected search for both individual brands and more general product categories. They find a large and significant effect on brand searches and a smaller effect on category searches. 2 Lewis and Reiley (2013) show similar positive effects focusing on a range of consumer products advertised during the Super Bowl. Dinner et al. (2014) find cross-channel effects on sales: offline (online) advertising affects online (offline) sales. 3 The interaction of offline and online advertising is studied in Goldfarb and Tucker (2011) where they show that online ads can be a substitute for offline ads in affecting sales of alcoholic beverages. 4 An intensive debate also targets the second assumption that consumers receive a balanced understanding of the risks and benefits of taking a particular drug. One side of the debate argues that it is misleading to provide drug information to consumers as they cannot directly choose their prescription. To make things worse, pharmaceutical manufacturers may not have the incentive to provide "balanced" information: researchers show that television advertisements tend to emphasize drug benefits over risk information (Kopp and Bang 2000; Day 2006 ) and although most prescription drug websites provide both risk and benefit information, the risk information is presented in a less prominent and accessible way (Huh and Cude 2004) . Other evidence confirms the concern that consumer pressure for advertised drugs may compromise doctors' prescription choices (Kravitz et al. 2005) or lead to adverse drug-related events (David, et al. 2010 ). 5 The other side of the debate stresses the educational value of drug advertising: it informs consumers of a drug's existence, which may prompt consumers to research the drug, associate it with self-observed symptoms and eventually seek treatment. For example, Iizuka and Jin (2005) show that DTCA is associated with increased doctor visits, while Avery et al. (2007) show that DTCA has a positive and significant impact on antidepressant use. Two other papers conclude the net effect of DTCA is positive for consumers, focusing on cholesterol-reducing drugs, statins. Jayawardhana (2013) finds positive consumer welfare effects of DTCA, while Sinkinson and Starc (2015) show that DTCA is a cost-effective solution from a societal perspective. 6 Implicit in the FDA's 1997 guidelines regarding the adequate provision of package labeling in broadcast advertisements is that consumers could access detailed and balanced information about a drug at an alternative source, including the internet. While some consumers may directly navigate to the drug or pharmaceutical company's website featured in the advertisment, it is likely that others may use a search engine to query the drug or condition. Our paper first addresses that question: do consumers search for online information upon exposure to direct-to-consumer advertising (DTCA)? If they do, the search engine will provide a mixture of organic and paid links, some of which are primarily informational, while others could be more focused on promoting drug sales. Therefore, we examine the type of websites that consumers click to determine if the websites are more informational in nature (likely consistent with the FDA's intention) or more promotional. 7 The types of websites that consumers click play an important role on both sides of the DTCA debate. Finally, we consider the question of advertising spillovers: will DTCA encourage consumers to go beyond the advertised drug and research competing drugs? 8 Our analysis focuses on the click behavior of consumers using comScore's click-through data from the five largest search engines. According to Pew internet and the American Life Project (2008) 9 , search engines like Google and Yahoo! are an important gateway to the internet. Use of the internet in the U.S. increased from 52% of all American adults in 2000 to 84% in 2015 (Perrin 2015) . 10 When consumers go online, using a search engine is a very popular online activity: 91% of internet users visited a search engine in 2012 (Purcell 2012) . While consumers formerly relied on their doctor as the primary source of medical information, now they increasingly turn to the internet. A study by Pew Research found that 72% of internet users searched for health-related information on the internet in the past 12-months and 77% of users began at a search engine (Fox 2013 ). 11 Interestingly, while most DTCA for prescription drugs are conveyed via traditional medias such as television, radio, magazines, newspapers, and billboards, a small but growing portion is devoted to display (banner) advertisements and sponsored search on the internet. For example, pharmaceutical manufacturers spent $270 million on online display ads in 2010, 6.4% of overall DTCA spending. 12 Overall, total DTCA spending on prescription drugs increased from $662 million in 1996 (the year before the FDA's new guidance) to $4.2 billion in 2010, a 542% increase. According to Nielsen, in 2014, pharmaceuticals were the third largest category of ad spending. 13 Our analysis shows that advertising on a prescription drug serves to increase the frequency of online search for that drug as well as search for other drugs in the same class. 14 The number of clicks following drug queries is positively associated with DTCA and the effect is significantly larger for paid clicks compared to organic clicks. 15 Clicks (both organic and paid) on promotional websites are more strongly associated with DTCA compared to clicks on informational websites. The magnitude of the effect of DTCA varies significantly by media type. Broadcast, print, and internet advertising all show positive and significant effects, through broadcast ads show the largest effect on organic clicks while internet ads has the strongest association with paid clicks.
Because our comScore data are only available monthly, we supplement our analysis using daily 9 See http://www.pewinternet.org/~/media/Files/Reports/2008/PIP_Search_Aug08. pdf.
10 Figure A1 in the appendix shows the overall growth of U.S. internet users and the simultaneous increase in prescription drug expenditure. 11 Another survey finds that "approximately 40% of respondents with internet access reported using the internet to look for advice or information about health or health care in 2001." (Baker 2003 14 Our results show that class-level DTCA has a larger effect than own-drug DTCA, which is consistent with studies by Donohue and Berndt (2004) and Shapiro (2015) that show that DTCA (unlike detailing to a physician) has more of an effect on market expansion than on specific drug choice. 15 When a user submits a query on a search engine, the engine returns both a list of links based only on the engine's search algorithm and additional links that are based on their relevance to the query and a payment made by the link's owner. The former are called organic links and the latter are called paid or sponsored links.
Google Trends data and daily DTCA on television. Our findings using the comScore data are confirmed by a positive relationship between the higher-frequency DTCA and Google Trends index, suggesting that consumers' internet search responds to television ads quickly.
We also find the relationship between DTCA and search is stronger for younger drugs and for those drugs that treat acute conditions. This group of drugs may be particularly important from the FDA's point of view because consumers may be first-time users and lack experience taking a drug. As expected, drugs that are less likely to be covered by insurance plans also show a stronger (though insignificant) relationship between DTCA and search activity, particularly paid clicks on promotional websites. Ippolito and Mathios (1991) show that older and potentially more informationally-disadvantaged populations are more responsive to advertising. 16 If the advertising is associated with more clicks on promotional websites, it may expose these populations to relatively more biased and less balanced information. However, if the advertising is associated with clicks on informative websites, they also may benefit more than other populations if they lack awareness of alternatives. Our results show more evidence of the first hypothesis, primarily for older searchers. Promotional clicks are more strongly associated with DTCA for older searchers. In contrast, the relationship between DTCA and promotional clicks is reduced for less wealthy searchers. Neither age nor income level appears to affect the relationship between DTCA and clicks on informational websites.
The remainder of this paper is organized as follows. In section 2, we provide a description of the data, which includes click-through data from comScore, drug information from the FDA, and advertising data from Kantar Media. Section 3 presents summary statistics on drug-related searches and advertising. Regression results are presented in section 4 that show how DTCA is associated with the frequency of search and clicks following drug queries. We then show that our results are confirmed using a higher-frequency search index from Google Trends. We also consider spillovers of drug DTCA to other drugs in the same class and how drug attributes and searcher demographics affect the relationship between advertising and search. Section 5 concludes.
Search Data
Search and click-through data are based on a 37-month sample (September 2008-September 2011) from comScore for 373 prescription drugs. 17 ComScore's data is based on a sample of approximately one million households in the U.S., which when combined with various demographic weights, is representative of the aggregate activity of all U.S. internet users. 18 ComScore's Search Planner product provides the frequency of searches and clicks for a given query (drug) on the five largest internet search engines (Google, Yahoo!, Bing, AOL, and Ask) for all U.S. internet users. 19 Reports are generated for both "exact" queries (i.e., the metrics reported are for searches on the precise query entered into the search engine) and "match-all-form" queries (i.e., the metrics reported are for searches on the precise query and alternative forms of the query such as additional words, plural forms, and common misspellings). 20 Most of our analysis will rely on the match-all-forms reports though results using the exact reports are provided in the appendix.
To request the search data from comScore, we needed to provide a list of queries on which to generate the reports. To create the database of queries, we use the FDA's Orange Book, which includes all drugs that have been approved by the FDA. 21 We focus on drug names only (as opposed to medical conditions and drug classes) because drug names are mentioned prominently (and repeatedly) in advertisements and one study found that over 80% of drug advertisements promoted specific products rather than medical conditions. 22 Because many of these drugs are unpopular or have more obscure names, we first ran the full list of drug names through comScore to download the search activity during the first and last six months of our sample period. Drugs with no search activity in either window were dropped, leaving us with a sample of 2,158 drugs. After merging with the advertising database and restricting to drugs that have positive ads in at least one month during our time period, we are left with 373 drugs on which we perform our analysis. 23 ComScore also 17 Because 51 drugs are newly approved during our sample period, we only include the period after approval for those drugs. 18 The comScore data has been used in many studies including Chiou and Tucker (2016) and George and Hogendorn (2013). 19 Throughout this paper, we use the term "query" to designate the search term a consumer enters in a search engine. In our case, queries are drug names. See https://www.comscore.com/Products/Audience-Analytics/ Search-Planner. 20 The match-all-forms report for the query "lipitor" would include metrics for "buy lipitor", "lipetor", "lipitor side effects," etc. 21 At the time of download, the Orange Book included 26,590 drugs. 22 See http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690298/ for more on the evolution of drug advertising in the U.S. Prior to the FDA's 1997 guidelines, broadcast ads generally featured either the drug name or the condition treated, but not both. 23 ComScore censors the search and click reports if the sample size is too small to reliably extrapolate to the population. This is less of an issue for our sample of drugs that are all actively advertised. Approximately 15% of drug-months show zero searches and clicks, which could be due to censoring. To the extent these zeros should be positive, our analysis may underestimate the effects of advertising on search and clicks. All of the 373 drugs in the sample have searches and clicks in at least one month during our time period. Note the sample includes drugs that were 6 provides demographic information, including age and household income, for the average searcher of a given query. Descriptive statistics on the comScore click-through data are shown in Table 1 . Drugs in our sample received an average of about 40,000 searches each month and those searches generated approximately 28,000 clicks. 24 Almost 91% of clicks are on organic links, i.e., those displayed based only on the search engine's algorithm. The remaining clicks are on paid (or sponsored) links, which appear based both on their relevance to the search query and a payment made to the search approved in the middle of the sample period. 24 Note that searches (the act of typing a query into a search engine and seeing the results) may or may not be followed by one or more clicks. engine by the link's owner. The average searcher in our sample is 49 years old with a household income of over $81,000.
While many websites contain a mix of both marketing material encouraging the sale of a drug and information about the benefits and risks associated with a drug, we further classify clicks on websites as being primarily promotional or informational. Promotional clicks are those on online pharmacies (e.g., drugstore.com), brand websites (e.g., lipitor.com), and producer websites (e.g., pfizer.com). Informational clicks are those on websites ending in dot-gov (e.g., fda.gov), those ending in dot-edu (medicine.yale.edu), and general health information websites (e.g., webmd.com). 25 All other clicks are classified as "other" and they include clicks on non-health related websites and generally popular websites, such as yahoo.com. Promotional clicks are much more likely to be paid compared to informational clicks.
It is important to note that we are not viewing promotional websites as bad and informational websites as good, but simply classifying the websites based on their likely primary content. While Kim (2015) found that among 35 branded drug websites that received warning letters from the FDA, the most common alleged violation was the omission or minimization of adequate risk information, we do not attempt to assess the content of each website in terms of providing a fair balance of drug benefits and risks.
Advertising Data
We also gather data from Kantar Media on DTCA spending (in dollars) for each drug in the sample. The data are reported monthly from January 1994 through September 2011. 26 Although we observe DTCA separately by geographic area (e.g., ads that only run on television in a certain city), we focus on national advertising, which represents more than 90% of total DTCA spending. The data include 1,684 unique brand name drugs, of which 832 had positive DTCA between September 2008 and September 2011, the date range of the comScore data. Advertising expenditure is broken down by media type and the full time series of DTCA spending is shown in Figure 1 The growth of total DTCA is clearly evident with the largest increases in television and magazine advertising, and more recently, spending on the internet. In 2011, total DTCA was divided between television (53.1%), magazines (35.9%), internet (6.1%), newspapers (4.3%), radio (0.5%), and outdoor ads (0.02%). The growth in television advertising is particularly apparent following the FDA's new guidance on DTCA issued in 1997. Kantar only reports internet ad spending on display ads which appear, for example, across the top of many websites though generally not search engines. It does not include spending on sponsored/paid search results which is reported to be about the same size as display ad spending in the pharmaceutical industry. 28 Figure A2 in the appendix shows the 25 drugs with the largest DTCA spending in 2011.
Descriptive statistics of the advertising data for the 373 drugs we matched with the comScore data are shown in Table 2 . The average drug has close to one million dollars per month of DTCA, though the average is highly skewed as 66 drugs (18%) had monthly DTCA above the mean and 307 (82%) were below. On average, a drug is advertised approximately five months out of the year, while 29 drugs in the sample were advertised in every month of the sample period. Although the median DTCA expenditure across all drugs-months is zero, the total DTCA for the smoking-cessation drug, Chantix, was over $72 million in December 2009. Television, magazine, and, increasingly, internet-based advertising have the largest average monthly expenditure among the media channels. 
Drug Data
Finally, we gather characteristics of each drug in our sample from the FDA Orange Book as well as the MEPS from 2008-2011. Descriptive statistics on the variables used in the remainder of the paper are shown in Table 3 . Table 1 . Source: FDA Orange Book and MEPS. Statistics for age of drug based on the drug's age in the first month it appears in our sample. Brand is an indicator for a brand name drug. Chronic is an indicator that equals one if the median annual days supplied is more than 90 days. Insurance coverage measures the proportion of the total payment paid for by third parties. Rx per year is the average number of prescriptions written for a patient in a given year (irrespective of days supplied).
The average drug in our sample was approved by the FDA around the year 2001 and almost all drugs in our sample are brand name drugs. 29 We use the MEPS to identify drugs that more likely 29 For 7% of drugs in the sample, the drug is listed under its generic name. treat chronic and acute conditions. While there is not a precise definition of what constitutes a chronic condition, the academic literature and other health websites frequently use a three-month rule: if a condition persists for more than three months out of a year, the condition is classified as chronic. 30 We use this definition to classify drugs as treating chronic conditions if the median annual supply is more than three months. 31 In our sample 49% of drugs are classified as treating a chronic condition. The average days supplied for chronic drugs is just under six months, while the average for drugs treating acute conditions is 45 days.
For each drug, the MEPS reports the amount the customer pays for each prescription and the amount paid by third parties, such as private insurance and Medicare. The Insurance Coverage variable in the table is the ratio between what third parties pay and the total payment. Coverage for drugs in our sample ranges from 5% to 100% and averages approximately 76%. The variable Rx Per Year is the average number of prescriptions written for a patient each year. In our sample, the average drug is prescribed four times per year to a particular patient. 32 Finally, from the FDA's National Drug Code Directory, we obtain the therapeutic class to which each drug belongs (e.g., cardiovascular agents, respiratory agents, etc.). 33 
Descriptive Analysis
In this section we present general descriptive statistics on the advertising and search activity of drugs in our sample. Descriptive statistics on the 10 most advertised drugs are shown in Table 4 . 34 30 For example, see Ekelund and Persson (2003) and http://www.medicinenet.com/script/main/ art.asp?articlekey=2728. 31 Specifically, each year of the MEPS data are reported at the patient-drug-prescription level. For 2010 and 2011, the MEPS includes a variable that indicates the length of the prescription ("days supplied"). While over one-half of prescriptions are for a 30-day supply, a patient may be prescribed the same drug multiple times each year. Therefore, we aggregate the days supplied for each patient-drug-year and then calculate the median days supplied across patients. If this statistic is greater than 90 days, the drug is classified as treating a chronic condition. 32 Of course, prescriptions per year is highly correlated with the variable we use to classify drugs treating chronic conditions. For example, the flu prevention drug, Tamiflu, is prescribed an average of 1.04 times per year and has a median days supplied of five days. Opana is a pain medication with an average of seven prescriptions per year and a median days supplied of 300 days. Tamiflu is classified as an acute drug, while Opana is classified as a chronic drug. 33 A full list of drug classes is shown in Table A3 . See http://www.fda.gov/Drugs/ InformationOnDrugs/ucm142438.htm. 34 A similar table for the 10 most searched drugs is shown in the appendix table A1. DTCA, searches and clicks are month averages from 9/2008-9/2011. Age of drug, searcher age, and searcher income as of the first month a drug appears in the sample. Keywords are from the Kantar database of drug DTCA. Chronic drugs are those where the median annual days supplied is more than 90 days. Insurance coverage is the ratio of the total payment made by third parties (private insurance, Medicare, etc.) to the total payment (including payments by the patient).
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The list reveals that although most highly advertised drugs are also searched often, there is a wide range of drug ages, prescription rates, insurance coverage rates, and searcher demographics among these drugs. The cholesterol drug, Lipitor, has average DTCA of over $21 million a month and receives almost 140,000 searches. Averages of the key search and advertising variables for all drugs are shown in Table 5 . The average drug in our sample has total DTCA of $911,000 each month. Television DTCA represents about 58% of the total consumer-directed advertising budget for a drug. Over 90% of clicks are organic, and as shown in Figure 2 , this percentage has grown about eight percentage points from 2008 to 2011. 35 As a percentage of total clicks received, Table 5 shows that over twice as many clicks (33% versus 15%) are clicks on informational websites compared to promotional websites. Figure 2 also shows that clicks on informational websites have slightly increased between 2008 and 2011, while clicks on promotional websites have been falling (as a percentage of total clicks). 36 
Percent of Clicks
Year
Org-Info
Org-Promo Org-Other Paid-Info Paid-Promo Paid-Other 35 The growth in organic clicks relative to paid clicks is partially due to Google's ban on unapproved online pharmacies from advertising via paid links in February 2010. Other search engines followed suit in subsequent months. All of our regression specifications include month fixed effects to control for any effects of the ban. For more, see: Chesnes, Dai, and Jin (2017). 36 Informational (promotional) clicks represented 32% (19%) of clicks in 2008 and 34% (13%) of clicks in 2011. Note that percentages in Table 5 are across all years. Figure 3 shows the distribution of destination websites for organic and paid clicks. 37 Among organic clicks, over half of clicks following drug queries are on general health information websites, followed by clicks on the the brand website and other sites like major search engines. The distribution of paid clicks is quite different with over half going to brand websites, followed by general health websites and a significant fraction, 16%, to online pharmacies. 38 Figure A3 in the appendix shows the organic/paid split for each entity type ranging from online pharmacies with the highest percentage of paid clicks (52.2%) to dot-edu websites with the highest percentage of organic clicks (99.8%). 
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Notes: DTCA, searches and clicks are month averages from 9/2008-9/2011. Age of drug, searcher age, and searcher income as of the first month a drug appears in the sample. Chronic drugs are those where the median annual days supplied is more than 90 days. Insurance coverage is the ratio of the total payment made by third parties (private insurance, Medicare, etc.) to the total payment (including payments by the patient). Low coverage drugs are drugs where the percent of the total payment that is paid by third parties is less than 80% (the median coverage).
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Searcher Age Table 6 shows the monthly averages of key variables both by drug characteristics and searcher demographics. 39 Acute and chronic drugs are searched at approximately the same rate and receive a similar number of clicks following those searches. Users of chronic drugs may be seeking an inexpensive source of supply, though the percent of clicks on paid and promotional websites is approximately the same as acute drugs. These results hold, even though DTCA spending is over 1.6 times higher for drugs that treat chronic conditions compared to those that treat acute conditions.
Drugs that are less likely to be covered by third-party payers are searched much more often than drugs with high coverage, but again the percent of clicks on paid and promotional websites is similar for both high and low coverage drugs. If consumers are more likely to seek affordable supply options for drugs with low coverage, we might expect those drugs to receive a higher percentage of promotional clicks. However, if lower third-party coverage is correlated with lower per-prescription prices (and lower out-of-pocket expenditure), we would expect the opposite result. We explore this further in the regression analysis below.
The number of searches and subsequent clicks varies somewhat with searcher age and income -searchers in their late 40s and those with between $75,000 and $100,000 in income tend to search more than other groups, but the percent of clicks on paid and promotional links do not vary systematically. Tables showing these same variables by drug age (A2) and drug class (A3) are included in the appendix.
Regression Results
Our regression analysis is at the drug-month level. The breakdown of advertising by media is important both because of different FDA regulations over what must be conveyed in advertisements on each media and DTCA via different channels may have different effects on consumer search patterns. Because almost 90% of DTCA is either on television or in magazines, we aggregate DTCA into "broadcast" and "print" based ads. Television and radio DTCA are aggregated into the broadcast DTCA variable, while magazine, newspaper, and outdoor-based DTCA are aggregated into the print DTCA variable. We leave internet DTCA separate both because it is the fastest growing segment of DTCA and due to its close proximity to the variables we are measuring, search and clicks.
Broadcast media, especially since the FDA's guidance in 1997 lessening the requirements on what needs to be conveyed during the ad, tends to only highlight the main benefits and potential side effects of a drug (the "major statement"). Magazine ads usually include two pages: one with the highlights of the drug in full color and dramatic fonts, and the other with the details in fine print (the "brief summary"). DTCA in newspapers is likely presenting similar information to magazine ads. The internet ads captured in the data are display ads and would likely have a similar effect to broadcast DTCA with only the highlights presented. Therefore broadcast and internet ads, given their lack of detailed information, may have a stronger positive effect on search compared to print ads.
Baseline: Effects of DTCA on Consumer Search and Clicks
Our baseline regression is shown in equation 1.
Search for drug d in month m is regressed on advertising for the drug and advertising for other drugs (excluding drug d) in the same class. 40 We control for time effects with year-month fixed effects in all specifications. Due to the skewed distribution of search popularity for drugs in our sample, we also include drug fixed effects in all specifications. The regression results in appendix table A4 shows how the coefficients on DTCA change with different drug and time fixed effects. In one specification, we include drug class interacted with month-of-year fixed effects to control for any seasonal patterns among certain classes of drugs, such as smoking cessation drugs at the end of the year or allergy drugs in the spring. The changes in the coefficients of interest are minimal compared with our preferred specification that includes drug and year/month fixed effects. Our dependent variable is alternatively the number of searches, clicks, organic clicks, or paid clicks.
The specifications in the tables below each contain either overall DTCA for a drug or a breakdown of DTCA by the broadcast, print, and internet display channels. Particularly for online advertising, one might be concerned about endogeneity if advertisers plan their DTCA spending in expectation of its impact on online search. Most of our advertising is offline, which likely limits this endogeneity, though we investigate the issue further in section 4.2 using high frequency Google Trends search data and television ad data. Our main specifications use search and advertising in the same month, but we have shown that using previous month ads to further address endogeneity concerns has only a small effect on the coefficients of interest. Those results are are available from the authors upon request. 41 The use of contemporaneous advertising appears appropriate in light of the results based on daily Google Trends data, which show that consumer search responds almost immediately to daily ads and tends to dissipate after a few days.
Most of the DTCA in our data is offline with only 6% of total DTCA in the form of online display ads. Online spending on paid-search advertising is not included in the data. Particularly for specifications with paid clicks as the dependent variable, we are not accounting for a potentially important omitted variable, paid search advertising. To the extent that drug companies run simultaneous ad campaigns across channels, the reported coefficients will partially reflect the effect of the paid search ads. However, the bias should be limited because the correlation between internet (display) advertising and both broadcast and print ads is only 0.20, while it is 0.53 between broadcast and print ads. 42 Table 7 . 43 A drug's own and class DTCA are strongly associated with more search and clicks. The largest effect for own-drug DTCA is on paid clicks. A 10% increase in own-drug DTCA is associated with a 0.28%-0.33% increase in searches, all clicks, and organic clicks; and a 1.01% increase in paid clicks, statistically significantly higher than the effect on organic clicks. 44 Note that while the coefficient (elasticity) is larger for paid clicks compared to organic clicks, because most clicks are organic, the change in the absolute number of clicks is over twice as large for organic clicks. 45 We also find positive spillovers from one drug to another within the same class: class DTCA has larger effects than a drug's own DTCA for all clicks and organic clicks and a smaller effect for paid clicks.
Results of the baseline regression are presented in
Focusing on the breakdown by media category reveals that broadcast and internet advertising have positive and significant effects in most specifications, with the largest effect for paid clicks. This is consistent with the notion that these ads provide relatively less detailed information and may leave a consumer wanting to seek out additional sources. Print ads are positive and significant for all 43 Standard errors are clustered at the drug level. 44 To counteract the problem of multiple hypotheses, we adjust the p-values using the Bonferroni correction. The coefficients within each specification generally maintain the level of significance shown in Table 7 and the difference between the coefficients on Log(DTCA) in specifications (5) and (7) is significant at the 1% level. 45 In other words, while the marginal effect of DTCA is larger for paid clicks than for organic clicks, applying these elasticities to the average click volumes yields a larger absolute effect for organic clicks. From Table 1 , the average drug receives 25,214 organic clicks and 2,541 paid clicks each month. Multiplying these totals by the elasticities yields a change of 7,060 organic clicks and 2,566 paid clicks for a 10% increase in DTCA. specifications, though the coefficients are smaller in magnitude compared to broadcast ads. While overall class-level DTCA is significant for all and organic clicks, all the coefficients are insignificant when DTCA is broken out by channel. Class-level print-based DTCA is negative for all and organic clicks, consistent with consumers searching for the drug name appearing in those ads and clicking relatively less on drugs that may be in the same class. Overall, the magnitude of spillovers from class-level DTCA to clicks are largest for online ads. In Table 8 , we dig deeper into the effects of DTCA on clicks by separating promotional and informational clicks. As explained above, promotional websites include brand and producer websites as well as online pharmacies, while informational websites include dot-gov and dot-edu websites. Only a government agency can register for a website that ends in the dot-gov extension, only schools can use dot-edu, while anyone can register for a dot-com site (see Chesnes (2009) ). These three-letter extensions are called top-level domains. We believe that, particularly for complicated drug and health related information, a user processing the results of a search query will base their choice partially on the top-level domain and may prefer more exclusive domains (like dot-gov and dot-edu) if they are seeking unbiased information. Others may be seeking a place to buy a drug they have seen on television, so may be more likely to visit the drug company's website or an online pharmacy (both likely dot-com websites). 46 We find that DTCA is more strongly associated with promotional clicks than informational clicks, though the latter is still positive and significant. A 10% increase in DTCA is associated with a 0.68% increase in promotional clicks and a 0.28% increase in informational clicks, and these two effects are statistically significantly different from each other. 47 DTCA also has a significantly larger effect on paid promotional and paid informational clicks compared to organic promotional and organic informational clicks, respectively. As before, we can translate these marginal effects into absolute magnitudes: the coefficients on DTCA translate into an additional 2,916 promotional clicks and 2,536 informational clicks for each 10% increase in DTCA. 48 Class DTCA shows similar effects as own DTCA for promotional clicks, but the effect is not stronger for informational clicks as would be expected if ads for other drugs induce consumers to search for information about an underlying health condition or for alternative treatments. 49 The specifications using organic (promotional) clicks as the dependent variable show slightly lower (higher) effects of own-drug DTCA, though the differences compared to all clicks are insignificant.
The appendix includes various robustness checks on our baseline model. Table A5 shows that using logarithms of both the search and advertising variables provides a significantly better fit to the data (in terms of root MSE) than using levels. Table A6 shows that comScore's "exact" reports produce almost identical results to the specifications based on the "match-all-forms" reports. Alternative dependent variables are presented in Table A7 . While the results for searchers is very similar to the models based on searches, we also show that own DTCA has a positive, though only marginally significant, effect on the number of searches per searcher, implying a more in-depth search experience. Regressions using clicks on individual website types as the dependent variable are shown in Table A8 . The largest positive effects are for clicks on the brand, general health, and giant websites, while there are smaller positive effects for pharmacy and non-health related websites. Finally, in Table A9 , we focus on the rate of depreciation of DTCA. 50 Our baseline model (specification 1) is similar to the results based on the aggregate depreciated DTCA in the prior six months (specification 3), though the coefficient on own-DTCA is slightly smaller in magnitude. 51 47 The coefficients remain statistically significantly different at the 1% level using the Bonferroni correction. 48 From Table 1 , the average drug receives 4,288 promotional clicks and 9,056 informational clicks each month. Multiplying these averages by the estimated marginal effects yields the absolute changes in clicks on promotional and informational websites. 49 Note that while Table 8 presents results for promotional and informational clicks, the omitted category is "other clicks." A regression using "other clicks" as the dependent variable results in estimates similar to specification 4 for informational clicks (the coefficients on DTCA and class-DTCA are 0.021 and 0.039 respectively). Full results are available from the authors upon request. 50 Several researchers have attempted to estimate the depreciation rate of DTCA for prescription drugs. Berndt et al. (1995) find that about 15% of DTCA depreciated in a month (using data before the 1997 FDA clarification). Jin and Iizuka (2005) find that the effect of a drug's DTCA on the propensity of consumers to visit their doctor regarding the related drug class, depreciates by only about 4% per month. However, in Jin and Iizuka (2007), they find that the effect of DTCA on the likelihood that a doctor prescribes a drug is small and depreciates almost immediately. 51 We use a monthly discount rate of 0.9672 for the "6m Dep" variables in specification 3, which is the monthly depreciation rate of DTCA found in Jin and Iizuka (2005).
Google Trends Results
While comScore's search data allows us to separately identify the effects of advertising on the number of searches, organic clicks, paid clicks, and also analyze how these effects vary with searcher demographics and the type of websites that receive clicks, it suffers from being available only at a monthly frequency. At that frequency, one may be concerned about endogeneity: namely that both DTCA and search are both being influenced by unobserved factors or that DTCA spending is planned in expectation of consumer search. To address these concerns, we test the robustness of our results using daily Google Trends data and daily television advertising spending on 158 drugs from January 2004 to September 2011. 52 OLS regression results of the Google Trends index regressed on the log of DTCA, the log of class DTCA, and lags of both, are shown in Table 9 .
The various specifications include a different number of lags of ad spending in columns (1)-(3). 53 In columns (4)-(6), lags of the Google Trends index are also included. Drug and day fixed effects are included in all specifications. The effects of same-day and previous-day television advertising on the index are positive and significant in all specifications, ranging from 0.08-0.20 for same-day ads and 0.04-0.11 for previous-day ads. Previous-day class advertising is generally positive and significant, but other lags of class advertising are not statistically significant. We noticed the "last lag" of own-drug DTCA (e.g., t − 6 in specification (1) and t − 7 in specification (2)) is consistently positive, significant, and large in magnitude. The search index is serially correlated, so this motivated us to include lags of the search index in specifications (4)- (6) . This mitigates the issue and only slightly reduces the magnitude of the other coefficients of interest. 52 See https://trends.google.com/trends/. Google Trends data are available from 2004 and our advertising data run through September 2011. Google Trends data are available are higher frequencies, but download limitations allow us to only obtain daily data. The data are downloaded in 6-month intervals (due to a restriction by Google) and the index is rescaled relative to each 6-month window. Therefore, in order to create a complete time series over the full period, we downloaded monthly trends data (in one file) from 2004-2011, which has a consistent index for the full time period. Then using the method described by Eric Johansson (http://erikjohansson.blogspot. co.uk/2014/12/creating-daily-search-volume-data-from.html), we rescale the daily data using the monthly index. This method has been used in other papers including: http://iieng.org/images/ proceedings_pdf/9600E1014066.pdf. The 158 drugs are a subset of the drugs used in the main specifications of our paper that have television ads appearing during the sample period. 53 Specifications (3)-(6) also include an aggregate lag of all television ad spending two to four weeks prior to the date of the dependent variable. In addition to the OLS results, we also estimated autoregressive moving-average (ARMA) models using the same set of right-hand-side variables. The errors in these models are allowed to follow an autoregressive moving-average specification:
Results of these specifications are shown in Table A12 . The specifications presented vary the number of autocorrelation and moving-average terms. 54 The coefficients of Log(DTCA) remain positive and highly significant for day t through day t − 3. Their magnitude is generally declining in the lag length. Class DTCA is generally significant in day t − 1, similar to the OLS results. Including multiple lags in the error term (specifications (3)-(6)) has only a small effect on the coefficients of interest. 55 Overall, these results suggest that online search is reactive to television DTCA immediately. The effect lasts a few days and then becomes zero or negative. Therefore, it is hard to imagine how DTCA (especially offline televisions DTCA) is determined by an anticipated online search response. Similarly, Joo et al. (2016) find that "financial services brands did not use expectations about online search data in planning their advertising campaigns" and the authors "attach a causal interpretation" to their findings. 56 While it is difficult to compare the coefficients from these regressions to our main specifications (because the dependent variable is measured differently), they do suggest that there may be causal relationship between offline DTCA and online search that we continue to detect even at a monthly frequency.
Heterogeneous Effects: Drug Attributes
We next analyze how the effects of DTCA on search may be different for various types of drugs. Our model for these regression specifications is shown in equation 3.
log(search)
We include own-drug and class-level DTCA as independent variables as well as the interaction of drug attributes (X d ) with own-drug DTCA. Results are shown in Table 10 . Yes Notes: Standard errors clustered at the query level. *** p<0.01, ** p<0.05, * p<0.1. Match-all-forms comScore data. Drug age is standardized based on the age of the drug as of the first month it appears in the sample. Chronic drugs are those with a median annual days supplied of more than 90 days. Drugs with low insurance have a coverage rate below the median coverage rate across all drugs. Promotional clicks are those on pharmacy, brand and producer websites. Informational clicks are those on dot-edu, dot-gov, and other general health information websites.
The specifications correspond to all websites, promotional websites, and informational websites, separately for all, organic, and paid clicks. Drug attributes included are the drug's age since FDA approval, the type of condition the drug treats (chronic/acute), and an indicator for drugs with low insurance coverage. 57 For older drugs, DTCA is associated with fewer clicks, particularly promotional clicks. This may be because consumers are already aware of older drugs and are less influenced by their advertisements. 58 DTCA is generally less effective at driving clicks for drugs treating chronic conditions, potentially because consumers may be familiar with drugs they take frequently. 59 Though the coefficients are insignificant, DTCA is associated with more clicks for low coverage drugs, particularly paid clicks on promotional websites. This is consistent with the explanation that consumers are seeking an affordable supply source. Alternatively, studies have found that DTCA tends to be focused on drugs that improve a patient's quality of life and these drugs may be less likely to be covered by insurance. 60 The coefficient of DTCA on (all) informational clicks is positive (though insignificant) for drugs with low insurance coverage so a point of purchase may not 57 See appendix Table A10 for regression results showing how the effect of DTCA on search varies with a drug's class. Note these results are based on a smaller sample of drugs for which we observe drug characteristics. 58 Note that the drug age variable is standardized so other coefficients measure the effects for an average-aged drug (approximately seven years after FDA approval). 59 Our definition of chronic is based on a median days supply of at least 90 days. For robustness, we also considered a 180-day threshold and the results are even stronger (negative and significant), though only 24% of drugs in our sample are classified as chronic based on this definition. 60 Examples of these drugs include those treating hair loss and skin conditions. See Holmer (2002) . be the only motivation for these consumers. Consumers may be clicking on informational websites to obtain information on drug alternatives/equivalents that may offer better insurance coverage. If low insurance coverage and low per-prescription out-of-pocket drug prices were positively correlated, then consumers may have a reduced incentive to seek affordable sources of supply for drugs with low coverage. However, in the MEPS data, the correlation between out-of-pocket per-prescription drug costs and the proportion of the drug's total payment made by a third party is -0.23. Appendix Table A11 confirms this result: when we add the interaction of DTCA and out-of-pocket drug costs as an explanatory variable, the interaction of low insurance and DTCA remains positive, while the out-of-pocket interaction is negative and generally only significant for promotional clicks.
Heterogeneous Effects: Searcher Demographics
Finally, we turn to how searcher demographics affect the relationship between DTCA and search. Regressions in this section are similar to equation 3, but we replace drug attributes with searcher age and income from the comScore term profile reports. 61 Results are presented in Table 11 . Yes Notes: Standard errors clustered at the query level. *** p<0.01, ** p<0.05, * p<0.1. Match-all-forms comScore data. Promotional clicks are those on pharmacy, brand and producer websites. Informational clicks are those on dot-edu, dot-gov, and other general health information websites. Searcher age and income are standardized based on their values in the first month a drug appears in the data.
DTCA may have a larger effect on older and potentially more informationally-disadvantaged searchers, populations that may be more responsive to advertising if they have limited information and are not internet savvy enough to use online search. They may also benefit more from drug advertisements if they are relatively less aware of a drug's existence, the condition it treats, and its alternatives. Lower income searches may be more responsive to DTCA if it causes them to seek out affordable sources of supply.
We find that DTCA tends to have a stronger effect on promotional clicks for older searchers, consistent with the hypothesis that these searchers may be more informationally disadvantaged. Positive and significant effects are also found for paid promotional clicks by those with higher incomes. The fact that higher income searchers appear to be more responsive to DTCA is inconsistent with the hypothesis that lower income searchers may be more likely to seek out affordable supply in response to DTCA. Finally, none of the coefficients are significant for organic or informational clicks for these same populations.
Conclusion
Our analysis shows that consumers seek diverse information about prescription drugs online and their behavior is influenced by the online and offline advertising to which they are exposed. Our paper is careful not to claim that the relationship between DTCA and online search and clicks is causal. In any study that considers the effects of advertising on some dependent variable, the typical concern is that advertisers are planning their advertising campaigns with some knowledge of future market conditions that is unobserved to the researcher. Hence, advertising is endogenous. Some of the effects can be controlled using drug and time fixed effects (see Table A4 in the appendix). We also check for the robustness of our results using the one-period lag of DTCA as the explanatory variable and using higher-frequency Google Trends data. Lewis and Rao (2015) show that measuring the returns to advertising is extremely hard and advertisers are likely not responding to some unobserved information to place optimal ads in response to current and forecasted demand. In addition, Joo et al. (2014) find that "advertisers seldom coordinate television and search advertising campaigns" and there is little evidence that "brands planned advertising expenditures based on expectations of search." Therefore, the variation we have observed in the DTCA data can be exogenous and our coefficients may capture a causal effect.
Overall, we show that advertising on a prescription drug serves to increase the frequency of online search and subsequent clicks for that drug as well as search for other drugs in the same class. These results are confirmed using a higher-frequency search index from Google Trends. While broadcast and internet advertising have the strongest positive effects on paid clicks, the magnitude of the effect of DTCA varies significantly by media and click type. Following drug searches, the effect of DTCA on clicks varies both by the type of link (organic versus paid) and the type of destination website (informational versus promotional).
The effect of DTCA is significantly larger for paid clicks and promotional websites compared to organic clicks and informational websites respectively. The relationship between DTCA and clicks is stronger for younger drugs and for those drugs that treat acute conditions. Because these drugs are more likely to be prescribed to first-time users who may lack information about side effects, interactions, etc., the FDA may be reassured that consumers are seeking additional information. It is also encouraging that our results do not support the hypothesis that lower-income searchers are more likely to click on promotional links in response to DTCA.
However, DTCA is also associated with clicks on promotional websites, and positive (though insignificant) effects are found for drugs with low insurance coverage as consumers may be seeking an affordable supply source. For older searchers, a population that may be more responsive to advertising, clicks on promotional websites are more strongly associated with DTCA. Finally, while DTCA may be associated with more clicks on promotional websites, most of those clicks are on brand websites, which the FDA monitors in order to ensure balanced and unbiased information.
While these results are informative for DTCA for prescription drugs, one should be cautious when extending them to other consumer products. Drugs are unique in that they usually have a targeted audience, there are particularly salient risks and costs associated with bad information, and consumers are not making the final purchase decision since a physician must prescribe the drug. However, drugs are an important category to focus on because they are heavily regulated and continue to be one of the largest categories of advertising expenditure on television. 62 Overall, because the total number of clicks on organic links is about 10 times larger than clicks on paid links, the effect of DTCA on the absolute number of clicks is larger for organic links compared to paid links and roughly evenly split between informational and promotional websites. Without more information on drug prices and utilization, it is difficult to make conclusions regarding the welfare effects of DTCA. However, our research shows that at least for some drugs and demographic groups, DTCA is associated with consumers seeking additional information, which supports the FDA's intention when it adopted the 1997 guidelines. Yes Notes: Standard errors clustered at the query level. *** p<0.01, ** p<0.05, * p<0.1. Match-all-forms comScore data. Drug age is standardized based on the age of the drug as of the first month it appears in the sample. Chronic drugs are those with a median annual days supplied of more than 90 days. Drugs with low insurance have a coverage rate below the median coverage rate across all drugs. Promotional clicks are those on pharmacy, brand and producer websites. Informational clicks are those on dot-edu, dot-gov, and other general health information websites. Out-of-pocket drugs costs are standardized. Table A12 : Google Trends Regressions -ARMA Models (1) (2) (3) (4) (5) (6) VARIABLES Index (t) Index (t) Index (t) Index (t) Index (t) Index (t) Log DTCA (t) 0.123*** 0.083*** 0.083*** 0.085*** 0.084*** 0.083*** (0.008) (0.007) (0.007) (0.007) (0.007) (0.007) Log DTCA (t-1) 0.114*** 0.087*** 0.087*** 0.083*** 0.083*** 0.083*** (0.009) (0.007) (0.007) (0.007) (0.007) (0.007) Log DTCA (t-2) 0.034*** 0.027*** 0.027*** 0.024*** 0.024*** 0.024*** (0.010) (0.008) (0.008) (0.007) (0.007) (0.007) Log DTCA (t-3) 0.022** 0.021*** 0.021*** 0.022*** 0.023*** 0.022*** (0.009) (0.008) (0.008) (0.007) (0.008) (0.007) Log DTCA (t-4) 0.012 0.011 0.011 0.016** 0.015** 0.016** (0.010) (0.008) (0.008) (0.007) (0.007) (0.007) Log DTCA (t-5) 0.010 0.008 0.008 0.014* 0.014* 0.013* (0.009) (0.007) (0.007) (0.007) (0.007) (0. 
